Use of Gynecological Drugs Restricted In EU; ‘Urgent’ Safety Review Starts For Pholcodine
A Review Has Also Started For Topiramate
Executive Summary
The European Medicines Agency has completed its investigation into the safety of nomegestrol and chlormadinone, and has started reviewing risks linked to the cough suppressant, pholcodine, and the epilepsy and migraine drug, topiramate.
You may also be interested in...
Don’t Use Topiramate In Pregnancy Unless No Other Drug Is Available, Says EU Drug Safety Committee
The European Medicines Agency’s pharmacovigilance committee said its safety review of topiramate took account of available data including three recent observational studies.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.